ABBV and AMGN Related Headlines
Go Back- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
- Barclays launches U.S. biopharma coverage with four preferred picks
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
- This U.S. biotech stock is Bernstein's Top Pick for 2026
- Piper Sandler Highlights Top Picks in the Biopharma 2026 Preview Note
- Trump to announce prescription drug price agreements
- Bernstein on IRA pricing: $245 really is the floor
- Canaccord #1 Key Risk to AxoGen, Inc. (AXGN): 'the FDA running out of carryover funding and needing to halt work'
- FDA on Operations During Shutdown: 'FDA will not be able to accept any regulatory submissions for FY 2026 that require a fee payment'
- Bernstein on AmericasMedicines.com: 'The Noise Starts, But Not (Yet) from Trump'
- Trump demands pharma CEOs lower drug prices within 60 days
- Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
ABBV and AMGN Related Press Releases
Go Back- CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research
- Atopic Dermatitis Market to Accelerate at a Rapid Pace by 2034 with Advancements in Biologics and JAK Inhibitors | DelveInsight
